单次19 Gy高剂量率前列腺近距离放疗的健康相关生活质量与毒性:II期试验
本II期试验纳入43例低/中危前列腺癌患者,前瞻性评估单次19 Gy高剂量率近距离放疗(BRT-HDR-19 Gy)的毒性、耐受性及健康相关生活质量(HRQoL)。中位随访20个月,急性与晚期2级泌尿生殖毒性各发生于4例(9%),无3级毒性;EPIC尿急/梗阻评分在3个月时显著下降(p=0.047),6个月恢复基线,其他领域无显著变化。
要点
- 急性及晚期2级泌尿生殖毒性均为9%,无3级毒性。
- EPIC尿急/梗阻评分3个月时显著下降(p=0.047),6个月恢复基线。
- 6个月时患者满意度为「非常满意」23%、「极其满意」77%。
核心结论
- 单次19 Gy高剂量率前列腺近距离放疗在毒性、耐受性、安全性、患者满意度及HRQoL方面均表现优异。
研究设计与样本
- 2014年1月至2016年7月开展的前瞻性II期试验,纳入43例低/中危前列腺癌患者,接受单次19 Gy高剂量率近距离放疗并前瞻性监测毒性和HRQoL。
主要发现
- 中位随访20个月(4-26个月)期间,急性2级泌尿生殖毒性4例(9%),无急性胃肠道毒性;晚期2级泌尿生殖毒性4例(9%);无3级毒性。
- EPIC尿急/梗阻领域评分在3个月时显著下降(p=0.047),6个月时恢复基线;尿失禁、肠道、性功能及激素领域评分无显著变化。
- 6个月时患者满意度自评为「非常满意」23%、「极其满意」77%。
关键数值与推荐
- 中位年龄71岁(55-78),初始PSA 7.0 ng/mL(4.2-17.8),IPSS 5(0-14);低危44%、中危56%。
- 中位CTV-V100为96.5%,尿道Dmax为106%,直肠2 cc剂量为53%。
临床怎么用
- 对于低/中危前列腺癌患者,单次19 Gy高剂量率近距离放疗可作为毒性低、耐受性好且患者满意度高的治疗选择,需关注3个月时尿急/梗阻症状的一过性加重。
局限性
- 中位随访仅20个月,样本量43例,缺乏长期肿瘤学结局与对照比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety, tolerance and impact on health-related-quality-of-life (HRQoL) of the high-dose-rate brachytherapy of 19 Gy (BRT-HDR-19 Gy) single fraction in prostate cancer. METHODS: From January 2014 to July 2016, 43 patients with low/intermediate risk were treated with BRT-HDR-19 Gy. The patients were monitored prospectively for toxicity and HRQoL. RESULTS: The median age, initial PSA and the International Prostate Symptom Score (IPSS) were 71 years (55-78), 7.0 ng/mL (4.2-17.8) and 5 (0-14) respectively. 44% were low-risk and 56% intermediate-risk. Median CTV-V100 (where Vn is the fractional volume of the organ that receives n% of the prescribed dose) was 96.5%, Urethral-Dmax 106% and rectum-2 cc (the dose to 2 cc of rectal wall) 53%. After a median follow-up of 20 months (4-26), acute grade-2 genitourinary (GU) toxicity occurred in 4 patients (9%) and none presented acute gastrointestinal (GI) toxicity. Similarly, four patients (9%) presented late GU grade-2 toxicity. No grade-3 toxicity occurred. In terms of HRQoL, there was a statistically significant decline in Expanded Prostate Cancer Index Composite (EPIC) urinary urgency/obstructive domain at month 3 (p = 0.047), and returned to baseline by month 6. Mean EPIC urinary incontinence, bowel, sexual and hormonal domains did not present significant post BRT-HDR-19 Gy changes. Patients rated their satisfaction at 6 months as "very-satisfied" (23%) or "extremely-satisfied" (77%). CONCLUSIONS: BRT-HDR-19 Gy demonstrates excellent results in terms of toxicity, tolerance, safety, patient satisfaction and HRQoL.
引用
- Gomez-Iturriaga A, Casquero F, Pijoan JI, et al. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial. Radiother Oncol. 2017. PMID: 29153462. doi:10.1016/j.radonc.2017.10.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。